Alprazolam misuse: Analysis of French Addictovigilance Network data from 2011 to 2020

Archive ouverte

Diaz, Laurine | Eiden, Céline | Jouanjus, Emilie | Frauger, Elisabeth | Fouilhé, Nathalie | Djezzar, Samira | Gibaja, Valérie | Boucher, Alexandra | Le Boisselier, Reynald | Libert, Frédéric | Caous, Anne-Sylvie | Monzon, Emilie | Guerlais, Marylène | Daveluy, Amélie | Fauconneau, Bernard | Peyrière, Hélène

Edité par CCSD ; Elsevier Masson -

International audience. ObjectivesAlprazolam, a high-potency and short-acting anxiolytic benzodiazepine, is one of the most misused benzodiazepines in France. In the context of various reports on alprazolam misuse during the COVID-19 pandemic, the objective of this study was to assess alprazolam abuse potential by analyzing French addictovigilance and international data.MethodsData collected from 2011 to 2020 using the following epidemiological tools of the French Addictovigilance Network were analyzed: spontaneous reports (SRs), OPPIDUM (addiction care center data), OSIAP (falsified prescriptions), DRAMES (substance-related deaths), and chemical submission surveys. Moreover, the VigiBase™ database was analyzed to evaluate alprazolam abuse liability worldwide.ResultsDuring the study period, 675 SRs concerning alprazolam misuse were recorded (sex ratio: ̴1; median age: 39 years). The desired effects were intensification of the therapeutic anxiolytic effect, euphoric effect, and management of substance withdrawal. Alprazolam was the third and first benzodiazepine listed in OPPIDUM and OSIAP surveys. Analysis of the SR and OPPIDUM data showed a recent increase in the alprazolam-opioid combination. In DRAMES data, alprazolam was directly linked to 11 deaths (associated with opioids in 10/11). VigiBase™ data analysis highlighted that France was the third country with the most cases of alprazolam misuse. The disproportionality analysis showed that in France, alprazolam was associated with higher risk of misuse and dependence compared with other benzodiazepines: reporting odds ratio = 1.43, (95% CI: 1.04–1.95) and = 1.97 (95% CI:1.50–2.59), respectively.ConclusionsThis study highlighted an increase in various signals of alprazolam abuse in France, and an increased use of the alprazolam-opioid combination that was also linked to most of the recorded alprazolam-linked deaths. These signals have been reported also in the international literature, and should be thoroughly investigated.

Suggestions

Du même auteur

Evolution of the Addictovigilance Signal of Zopiclone: A 2014–2020 National Follow-up Study

Archive ouverte | Aquizerate, Aurélie | CCSD

International audience. Zopiclone, like zolpidem, is under surveillance in France due to its potential for dependence, abuse and misuse. However, part of the narcotics regulation was implemented in 2017 in France fo...

French national addictovigilance follow-up of zolpidem between 2014 and 2020: evolution of drug abuse, misuse and dependence before and after the regulatory change

Archive ouverte | Aquizerate, Aurélie | CCSD

International audience. Background Since the appearance of zolpidem on the market, the occurrence of serious cases of abuse, misuse and dependence have come to the attention of authorities. In view of the increase i...

Substance use disorder of equimolar oxygen-nitrous oxide mixture in French sickle-cell patients: results of the PHEDRE study

Archive ouverte | Gérardin, Marie | CCSD

International audience. Abstract Background In many countries, nitrous oxide is used in a gas mixture (EMONO) for short-term analgesia. Cases of addiction, with significant misuse, have been reported in hospitalized...

Chargement des enrichissements...